ISHL13 Program at a Glance

Saturday (26.10.2024)

Sunday (27.10.2024)

Monday (28.10.2024)

Großer Saal

08:00–09:30
Pediatric and Adolescent Treatment Concepts

J. Friedberg
C. Mauz-Körholz

Recent achievements and future goals in Pediatric and Young Adult HL: COG Perspective
- S. Castellino
Recent achievements and future goals in Pediatric and Young Adult HL: EuroNET-PHL Perspective
- C. Mauz-Körholz
Appropriate endpoints for future trials in Pediatric and Young Adult HL, and opportunities for harmonization
- J. Flerlage
- K. Kelly
EFFICACY and TOLERABILITY in DECOPDAC21 versus COPDAC28 in PEDIATRIC INTERMEDIATE and ADVANCED STAGE CLASSICAL HODGKIN LYMPHOMA: INTERIM RESULTS of the EURONET-PHL-C2 RANDOMIZED STUDY
- D. Körholz
Progression-Free Survival (PFS) with Nivolumab-AVD is superior to Brentuximab Vedotin-AVD with 2-year follow-up of S1826 in Adolescent Advanced Stage (AS) Classic Hodgkin Lymphoma (cHL)
- S. Castellino
Updated Results from the Phase 2 KEYNOTE-667 Study: Pembrolizumab (pembro) in Children and Young Adults With Low-Risk Classical Hodgkin Lymphoma (cHL) and Slow Early Response (SER) to Front-Line Chemotherapy (chemo)
- K. Kelly

Großer Saal

08:00–09:00
Special Situations & Cases

A. Fosså
A. Sureda

Treatment Approaches in Ressource Constraint Settings
- C. Asirwa
- O. Baiocchi
HL Richter Transformation Pathologists perspective
- S. Hartmann
HL Richter Transformation HL perspective
- M. Hertzberg
HL Richter Transformation CLL perspective
- O. Al-Sawaf

08:00

Marsilius Saal

08:30–11:00
Working towards harmonization of clinical trial reporting in Hodgkin Lymphoma (Separate registration required)

S. Barrington
S. Borchmann
C. Kobe
W. Plattel
D. Rossi

Großer Saal

08:30–11:00
EHA-LYG / GHSG Joint Educational “Emerging Therapeutic Concepts in B-Cell Lymphomas”

I. Aurer
B. von Tresckow

Introduction
Molecular and microenvironmental vulnerabilities of B-cell lymphomas
- S. Leppä
Is there a role for CAR T-cell therapy in first-line Tx of indolent lymphoma?
- M. Kersten
Who needs bispecific antibodies as first-line treatment in aggressive lymphoma?
- C. Thieblemont
How to implement novel ADCs in the first-line treatment of lymphoma
- P. Zinzani
Perspectives of small molecule based first-line therapy of LBCL
- T. Vasilakopoulos
Treatment and Trial Landscape for Malignant Lymphoma in China
- Y. Song

09:00

Coffee Break

Großer Saal

09:15–10:15
NLPHL

R. Hoppe
W. Klapper

NLPHL: HL, NHL or something else?
- S. Hartmann
First-line treatment of NLPHL with HL-directed approaches
- D. Eichenauer
Treatment of NLPHL with NHL-directed approaches
- G. Collins
Q&A
- G. Collins
- E. Dennis
- S. Hartmann

09:15

Coffee Break

Großer Saal

10:00–11:30
Biology & Microenvironment

S. Leppä
M. Shipp

Pathogenesis of HL
- R. Küppers
Multimodal characterization of cHL
- C. Steidl
Characterization of cancer-associated fibroblasts and their spatial architecture reveals heterogeneity and survival associations in classical Hodgkin lymphoma
- K. Karihtala
Circulating tumor DNA sequencing facilitates biological classification and individualized risk stratification in patients with Hodgkin lymphoma
- M. Heger
Distinct cell state ecosystems for nodular lymphocyte-predominant Hodgkin lymphoma
- M. Binkley
Multi-Dimensional Profiling Unveils Distinct Molecular Subtypes in Classic Hodgkin Lymphoma
- T. Aoki

10:15

Coffee Break

Großer Saal

10:30–12:00
Living Beyond Lymphoma

J. Radford
F. van Leeuwen

Late consequences of drugs used in the modern era of treatment for HL (to include anthracyclines, bleomycin, checkpoint inhibitors, ADCs)
- S. Ansell
Starting Living beyond Lymphoma with HL diagnosis
- K. Behringer
- M. Büttner
Participation in and (cost-)effectiveness of the Dutch HL survivorship care program
- B. Aleman
- A. Nijdam
A priori estimation of mediastinal toxicities after radiotherapy for Hodgkin Lymphoma - A secondary analysis of the HD16/17 Trial by the German Hodgkin Study Group using normal tissue complication probability calculations
- M. Oertel
Concordance between late effects reported by physicians and patients in a cohort of long-term Hodgkin lymphoma survivors: an analysis of data from nine consecutive EORTC-LYSA trials
- S. Juul
Novel 3D speckel tracking imaging modality in detecting cardiac toxicity in asymptomatic pediatric HL survivors
- Z. Salah Seliem

10:30

Coffee Break

Großer Saal

11:30–13:00
Limited Stages

M. André
L. Specht

IIntro: Treatment concepts in early-stage HL
- M. André
Viewpoint: Systemic Therapy only in the future?
- R. Advani
Viewpoint: CMT (is it there to stay?)
- J. Yahalom
Factors driving treatment intensity in the whole cohort of patients with early-stage favorable (I-IIA), nonbulky Hodgkin Lymphoma enrolled in the RAFTING trial (NCT 04866654).
- A. Gallamini
Nodular lymphocyte predominant Hodgkin lymphoma in the Nordic countries – characteristics, treatment and survival
- I. Glimelius
Serum TARC Dynamics Correlate with Clinical Response and Metabolic Tumor Volume During Anti-PD1-Based First-Line HL Treatment in The GHSG Phase II NIVAHL Trial
- W. Plattel

Coffee Break

12:00

Großer Saal

12:00–13:30
New concepts for the treatment of B-cell lymphomas

by MSD Sharp & Dohme GmbH

P. Borchmann

B-cell lymphoma pathology – illustrated for non- pathologists
- W. Klapper
Classical Hodgkin Lymphoma - Development of immune checkpoint inhibition beyond PD-1 blockade
- P. Borchmann
Diffuse Large B-cell Lymphoma - The current and future role of ADC in the context of immunotherapies
- S. Dietrich

Coffee Break

Großer Saal

12:30–14:00
Relapsed & Refractory HL

P. Armand
C. Moskowitz

Updated approach to second-line treatment
- A. Moskowitz
Emerging strategies to overcome anti-PD1 resistance
- S. Ansell
Implementing raditoherapeutic concepts in rrHL care
- C. Baues
Brentuximab Vedotin - ESHAP Significantly Increases the Metabolic Complete Remission Rate versus ESHAP in Relapsed Classical Hodgkin’s Lymphoma. Final Results of the BRESELIBET Prospective Trial.
- A. Sureda
Longitudinal circulating tumor DNA sequencing may predict the response to PD1 blockade therapy in relapsed/refractory classical Hodgkin Lymphoma patients
- F. Corrado
Pembrolizumab maintenance instead of autologous hematopoietic cell transplantation for patients with relapsed or refractory Hodgkin lymphoma in complete response after pembrolizumab, gemcitabine, vinorelbine, and liposomal doxorubicin
- A. Moskowitz

12:30

Großer Saal

13:15–14:45
The evolving role of BTKis in the treatment of B-cell lymphomas

by BeiGene Switzerland GmbH

C. Buske

Welcome and Introduction
- C. Buske
BTKis in indolent lymphomas (FL, MZL)
- C. Thieblemont
BTKis in WM
- C. Buske
BTKis in MCL
- D. Lewis
Future developments (CDAC, BCL2, anti PD1/PDL1)
- A. Frustaci
Panel discussion, audience Q&A
Closure and farewell
- C. Buske

Coffee Break

14:00

Großer Saal

14:00–15:30
Older Patients

P. Bröckelmann
A. Evens

Implementing Frailty Assessment for Treatment Guidance in HL
- S. Rutherford
Optimal Use of Targeted Agents to Address Unmet Need in Older HL
- G. Collins
A simplified frailty score predicts outcome in older patients with classical Hodgkin lymphoma treated with curative intent
- K. Lia
Characterisation of older Hodgkin Lymphoma patients using UK registry data from 1997-2023
- A. Barrett
Feasibility and Efficacy of PET-guided BrECADD in Older Patients with Advanced-Stage classical Hodgkin Lymphoma: The Older Cohort of the International GHSG HD21 Trial
- J. Ferdinandus
Nivolumab-AVD improves 2-year progression-free and overall survival compared to Bv-AVD in older patients aged ≥60 years with advanced stage classical Hodgkin lymphoma (cHL) enrolled on SWOG S1826
- S. Rutherford

Großer Saal

14:00
Closing remarks

R. Advani
S. Barrington
S. Borchmann
C. Kobe
W. Plattel

Workshop Report
- S. Barrington
- S. Borchmann
- C. Kobe
- W. Plattel
- D. Rossi
Best of ISHL13
- R. Advani
Farewell
- P. Borchmann

Coffee Break

Großer Saal

15:15–17:00
Opening and Award Ceremony

Welcome Address
- P. Borchmann
- V. Diehl
Award Ceremony
- P. Borchmann
- S. Borchmann
- P. Bröckelmann
- D. Eichenauer
Keynote Lecture
- L. Partridge

15:15

Coffee Break

Großer Saal

16:00–17:30
Real world impact: bridging between clinical trial and real world experience in stages III & IV 1L Hodgkin Lymphoma

by Takeda Pharmaceuticals USA, Inc.

J. Radford

Welcome and introduction
Spotlight on ECHELON-1: 7-year survival data
- J. Radford
Real-world insights: frontline treatment of stages III & IV cHL
- C. Rusconi
Q&A
cHL in the real-world: a case study approach
- C. Mahuad
- J. Radford

17:00

Coffee Break

Foyer (First Floor)

17:15–20:00
Poster Session & Welcome Reception

All poster presenters are required to be present at their poster boards from 17:15 to 19:00

17:15

Coffee Break

Großer Saal

18:00–19:30
Advanced Stages

A. Herrera
J. Zijlstra

Individualized treatment de-escalation improves overall outcomes
- P. Borchmann
Immune-chemotherapy overcomes the need for individualization
- J. Friedberg
2-Year Follow-up of the S1826 Study Confirms Improved Progression-Free Survival with Nivolumab-AVD Compared to Brentuximab Vedotin-AVD in Advanced Stage Classic Hodgkin Lymphoma
- A. Herrera
Development and application of a validated MRD assay in Hodgkin Lymphoma
- J. Mattlener
EORTC-1537-COBRA: PHASE II STUDY OF VERY EARLY FDG-PET-RESPONSE ADAPTED TARGETED THERAPY FOR ADVANCED HODGKIN LYMPHOMA. PRIMARY ANALYSIS INCLUDING VALUE OF QUANTITATIVE PET ASSESSMENT AND TARC DYNAMICS
- M. Hutchings
Metabolic tumor volume after two cycles of chemotherapy in patients treated for advanced-stage Hodgkin Lymphoma: analysis of the German Hodgkin Study Group phase III HD18 and HD21 trials
- J. Ferdinandus

20:00

08:00–09:30 Pediatric and Adolescent Treatment Concepts

Recent achievements and future goals in Pediatric and Young Adult HL: COG Perspective

Recent achievements and future goals in Pediatric and Young Adult HL: EuroNET-PHL Perspective

Appropriate endpoints for future trials in Pediatric and Young Adult HL, and opportunities for harmonization

EFFICACY and TOLERABILITY in DECOPDAC21 versus COPDAC28 in PEDIATRIC INTERMEDIATE and ADVANCED STAGE CLASSICAL HODGKIN LYMPHOMA: INTERIM RESULTS of the EURONET-PHL-C2 RANDOMIZED STUDY

Progression-Free Survival (PFS) with Nivolumab-AVD is superior to Brentuximab Vedotin-AVD with 2-year follow-up of S1826 in Adolescent Advanced Stage (AS) Classic Hodgkin Lymphoma (cHL)

Updated Results from the Phase 2 KEYNOTE-667 Study: Pembrolizumab (pembro) in Children and Young Adults With Low-Risk Classical Hodgkin Lymphoma (cHL) and Slow Early Response (SER) to Front-Line Chemotherapy (chemo)

08:00–09:00 Special Situations & Cases

Treatment Approaches in Ressource Constraint Settings

HL Richter Transformation Pathologists perspective

HL Richter Transformation HL perspective

HL Richter Transformation CLL perspective

08:30–11:00 Working towards harmonization of clinical trial reporting in Hodgkin Lymphoma (Separate registration required)

08:30–11:00 EHA-LYG / GHSG Joint Educational “Emerging Therapeutic Concepts in B-Cell Lymphomas”

Introduction

Molecular and microenvironmental vulnerabilities of B-cell lymphomas

Is there a role for CAR T-cell therapy in first-line Tx of indolent lymphoma?

Who needs bispecific antibodies as first-line treatment in aggressive lymphoma?

How to implement novel ADCs in the first-line treatment of lymphoma

Perspectives of small molecule based first-line therapy of LBCL

Treatment and Trial Landscape for Malignant Lymphoma in China

09:15–10:15 NLPHL

NLPHL: HL, NHL or something else?

First-line treatment of NLPHL with HL-directed approaches

Treatment of NLPHL with NHL-directed approaches

Q&A

10:00–11:30 Biology & Microenvironment

Pathogenesis of HL

Multimodal characterization of cHL

Characterization of cancer-associated fibroblasts and their spatial architecture reveals heterogeneity and survival associations in classical Hodgkin lymphoma

Circulating tumor DNA sequencing facilitates biological classification and individualized risk stratification in patients with Hodgkin lymphoma

Distinct cell state ecosystems for nodular lymphocyte-predominant Hodgkin lymphoma

Multi-Dimensional Profiling Unveils Distinct Molecular Subtypes in Classic Hodgkin Lymphoma

10:30–12:00 Living Beyond Lymphoma

Late consequences of drugs used in the modern era of treatment for HL (to include anthracyclines, bleomycin, checkpoint inhibitors, ADCs)

Starting Living beyond Lymphoma with HL diagnosis

Participation in and (cost-)effectiveness of the Dutch HL survivorship care program

A priori estimation of mediastinal toxicities after radiotherapy for Hodgkin Lymphoma - A secondary analysis of the HD16/17 Trial by the German Hodgkin Study Group using normal tissue complication probability calculations

Concordance between late effects reported by physicians and patients in a cohort of long-term Hodgkin lymphoma survivors: an analysis of data from nine consecutive EORTC-LYSA trials

Novel 3D speckel tracking imaging modality in detecting cardiac toxicity in asymptomatic pediatric HL survivors

11:30–13:00 Limited Stages

IIntro: Treatment concepts in early-stage HL

Viewpoint: Systemic Therapy only in the future?

Viewpoint: CMT (is it there to stay?)

Factors driving treatment intensity in the whole cohort of patients with early-stage favorable (I-IIA), nonbulky Hodgkin Lymphoma enrolled in the RAFTING trial (NCT 04866654).

Nodular lymphocyte predominant Hodgkin lymphoma in the Nordic countries – characteristics, treatment and survival

Serum TARC Dynamics Correlate with Clinical Response and Metabolic Tumor Volume During Anti-PD1-Based First-Line HL Treatment in The GHSG Phase II NIVAHL Trial

12:00–13:30 New concepts for the treatment of B-cell lymphomas

B-cell lymphoma pathology – illustrated for non- pathologists

Classical Hodgkin Lymphoma - Development of immune checkpoint inhibition beyond PD-1 blockade

Diffuse Large B-cell Lymphoma - The current and future role of ADC in the context of immunotherapies

12:30–14:00 Relapsed & Refractory HL

Updated approach to second-line treatment

Emerging strategies to overcome anti-PD1 resistance

Implementing raditoherapeutic concepts in rrHL care

Brentuximab Vedotin - ESHAP Significantly Increases the Metabolic Complete Remission Rate versus ESHAP in Relapsed Classical Hodgkin’s Lymphoma. Final Results of the BRESELIBET Prospective Trial.

Longitudinal circulating tumor DNA sequencing may predict the response to PD1 blockade therapy in relapsed/refractory classical Hodgkin Lymphoma patients

Pembrolizumab maintenance instead of autologous hematopoietic cell transplantation for patients with relapsed or refractory Hodgkin lymphoma in complete response after pembrolizumab, gemcitabine, vinorelbine, and liposomal doxorubicin

13:15–14:45 The evolving role of BTKis in the treatment of B-cell lymphomas

Welcome and Introduction

BTKis in indolent lymphomas (FL, MZL)

BTKis in WM

BTKis in MCL

Future developments (CDAC, BCL2, anti PD1/PDL1)

Panel discussion, audience Q&A

Closure and farewell

14:00–15:30 Older Patients

Implementing Frailty Assessment for Treatment Guidance in HL

Optimal Use of Targeted Agents to Address Unmet Need in Older HL

A simplified frailty score predicts outcome in older patients with classical Hodgkin lymphoma treated with curative intent

Characterisation of older Hodgkin Lymphoma patients using UK registry data from 1997-2023

Feasibility and Efficacy of PET-guided BrECADD in Older Patients with Advanced-Stage classical Hodgkin Lymphoma: The Older Cohort of the International GHSG HD21 Trial

Nivolumab-AVD improves 2-year progression-free and overall survival compared to Bv-AVD in older patients aged ≥60 years with advanced stage classical Hodgkin lymphoma (cHL) enrolled on SWOG S1826

14:00 Closing remarks

Workshop Report

Best of ISHL13

Farewell

15:15–17:00 Opening and Award Ceremony

Welcome Address

Award Ceremony

08:00–09:30
Pediatric and Adolescent Treatment Concepts

08:00–09:00
Special Situations & Cases

08:30–11:00
Working towards harmonization of clinical trial reporting in Hodgkin Lymphoma (Separate registration required)

08:30–11:00
EHA-LYG / GHSG Joint Educational “Emerging Therapeutic Concepts in B-Cell Lymphomas”

09:15–10:15
NLPHL

10:00–11:30
Biology & Microenvironment

10:30–12:00
Living Beyond Lymphoma

11:30–13:00
Limited Stages

12:00–13:30
New concepts for the treatment of B-cell lymphomas

12:30–14:00
Relapsed & Refractory HL

13:15–14:45
The evolving role of BTKis in the treatment of B-cell lymphomas

14:00–15:30
Older Patients

14:00
Closing remarks

15:15–17:00
Opening and Award Ceremony

16:00–17:30
Real world impact: bridging between clinical trial and real world experience in stages III & IV 1L Hodgkin Lymphoma

17:15–20:00
Poster Session & Welcome Reception

18:00–19:30
Advanced Stages